TrialCirculation2020

Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.

Amy Damask et al.PubMed ↗Publisher ↗

No numbers read from the abstract.